DISCOVER CUTTING EDGE TRANSLATIONAL CANCER RESEARCH AT QUEEN'S
Queen's translational cancer research is dynamic, globally collaborative and encompasses various fronts in the battle against cancer, including genetics/epigenetic research, drug design and development, immunology research, radiotherapy techniques and the study of the tumor microenvironment.
Through these multifaceted approaches, Queen's translational cancer research aims to pioneer innovative strategies for early detection, effective treatment, and ultimately, the eradication of cancer.
GENETICS AND EPIGENETICS
Genetics and epigenetics studies at Queen’s unravel the intricate molecular mechanisms underlying cancer initiation and progression, providing invaluable insights into potential therapeutic targets.
- Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission
- DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
- Pathway and network analysis of more than 2500 whole cancer genomes
- MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
DRUG DEVELOPMENT
Drug development initiatives at Queen’s have researchers striving to engineer novel compounds and therapies tailored to combat specific cancer types, fostering hope for improved treatment outcomes.
- CV6 Therapeutics to commence UK-wide clinical trial for first of its kind anti-cancer drug
- Drug-polymer miscibility and interaction study as a preliminary step in amorphous solid dispersion development: comparison of theoretical and experimental data
- Transcription factor activities enhance markers of drug sensitivity in cancer
- 3D printing: an appealing technology for the manufacturing of solid oral dosage forms
IMMUNOLOGY
Groundbreaking research is being undertaken at Queen’s, focusing on understanding the role of the immune system in health and disease, with a particular emphasis on the complex interaction between the immune system and infections. Our immunologists have a strong research focus on innate and adaptive inflammatory responses associated with diseases such as allergy, infection, and autoimmunity.
Read more about Queen’s immunology research and the harnessing of the power of the immune system to treat acute and chronic diseases.
TUMOR MICOENVIRONMENT
Researchers at Queen’s focus on understanding the intricate dynamics of the tumor microenvironment, recognizing its role in tumor growth, metastasis, and therapeutic resistance.
- Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach
- Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.
TUMOR MICOENVIRONMENT
- An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution
- Topography of cancer-associated immune cells in human solid tumors
- Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer
- Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
BREAST RADIOLOGY AND RADIOTHERAPY
From discovery to recovery, Queen's has been at the forefront of pioneering research in breast radiology and breast cancer treatment. This innovative research not only enhances early detection and diagnostic accuracy through cutting-edge imaging techniques but also explores novel treatments and therapies, offering hope to those affected by breast cancer and related conditions.
Read more about Queen's research advancements that improve the lives of individuals impacted by breast diseases.
ECONOMIC REVIEWS & THE FUTURE OF CANCER CARE
In the UK, 1 in every 2 people are projected to be impacted by cancer, with the rates expected to rise. The National Health Service in the UK is confronting significant shortages in its workforce, and cancer care has encountered difficulties in recovering from the repercussions of the COVID-19 outbreak. Researchers at Queen's aspire to contribute to the creation of innovative but viable strategies that are thorough, grounded in evidence, inclusive, prioritize patient-first approaches, and offer cost-effective solutions.
ECONOMIC REVIEWS & THE FUTURE OF CANCER CARE
- Skin in the game: the cost consequences of skin cancer diagnosis, treatment and care in Northern Ireland
- A comparison of international modelling methods to evaluate health economics of colorectal cancer screening: a systematic review
- Cancer literacy - Informing patients and implementing shared decision making
- Impact of the COVID-19 pandemic on cancer care in Ireland - Perspectives from a COVID-19 and Cancer Working Group
- Don’t make cancer survivors pay twice—the right for them to be "forgotten" should be law everywhere